Rosetta Genomics said this week that it has entered a sponsored research arrangement with Tel Aviv University tech-transfer subsidiary Ramot to develop a delivery technology for microRNA mimic-based cancer therapies.
Researchers from the University of Colorado and Tel Aviv University have reported a case study that suggests fluorescence in situ hybridization-based testing may miss some ALK rearrangements in lung cancer patients who could benefit from Pfizer's Xalkori (crizotinib).
By Molika Ashford
In the hunt for the genetic causes of hearing loss in local populations, researchers at Tel Aviv University have taken up targeted genomic capture and deep sequencing to root out causative mutations.
In a recent paper, Shomron and colleagues write that miRNAkey "is an intuitive tool for the implementation of the first steps of analysis of deep sequencing data obtained in miRNA sequencing experiments."